Melbourne, 16 February 2026
CSL Seqirus, part of leading Australian biotechnology company CSL, has today announced that neffy® adrenaline (epinephrine) nasal spray is now available and has been approved for use in Australia for the emergency treatment of anaphylaxis in adults and children 15kg+ and aged four years and over.1
Anaphylaxis occurs after exposure to an allergen, such as food, medications and insect bites and stings, and can be life threatening if not immediately treated with adrenaline. 3
Adrenaline rapidly reverses the effects of the condition by reducing throat swelling, opening the airways, and maintaining heart function and blood pressure.3
Anaphylaxis rates have increased over recent decades.4
Australia has one of the highest documented rates of anaphylaxis hospital admissions in the developed world.5 Between 2015 and 2020, Australian public hospitals reported a 51% increase in emergency department presentations and a 35% increase in hospitalisations due to anaphylaxis.6,7
Professor Connie Katelaris AM, leading NSW allergist, welcomes the registration and availability of neffy in Australia.
“The approval of neffy is very welcome as it gives patients and their doctors a nasal administration option and choice in managing their condition. It’s the first time in over 30 years that a new way of administering adrenaline has been approved in Australia.
“Anaphylaxis is a difficult condition to manage with some patients reporting challenges. neffy has been available for some time overseas and now patients in Australia will have access.”
Maria Said AM, Health Strategy and Advocacy Manager at Allergy & Anaphylaxis Australia, says the condition significantly impacts many Australians.
“Having a new treatment option which does not require injection will offer people at risk of anaphylaxis, and their treating doctor, the ability to choose an adrenaline device that best suits their needs from the range available.
“We know that people have to be extremely mindful of everyday things – such as eating at restaurants, attending social events, travelling or enjoying time outdoors. For parents of children with allergies, normal life experiences need to be planned for, including sleepovers, play dates, parties, air travel and school camps. Despite safety strategies being in place, accidents happen and people need to recognise an allergic reaction and respond quickly.”
Dr Jonathan Anderson, CSL Seqirus Executive Medical Director – International and GP, says the company is hoping to expand access to the treatment.
"This is an important treatment option and so today is a proud day for CSL Seqirus as an Australian company,” says Dr Anderson.
“We recognise the work by key Allergy Stakeholders in ensuring clinicians, consumers and school settings are prepared and supported for the introduction of neffy. We look forward to seeing decisionmakers assess our application for funding and working with them so that more Australians can access neffy.”
Healthcare organisations are updating their resources and anaphylaxis education to include neffy. Please visit their websites for further details.
About neffy
CSL has submitted an application for neffy to be subsidised and listed on the Pharmaceutical Benefits Scheme. The submission will be considered in March 2026.
neffy should be used at the first signs or symptoms of anaphylaxis. After using adrenaline patients should seek emergency medical assistance immediately for close monitoring and in the event further treatment is required. neffy should not be withheld from anyone who is considered to need it. Anaphylaxis treatment options and management should be discussed with a patient’s clinician. neffy is a registered prescription medicine and can only prescribed by a doctor.
Side effects:1 All medicines can have side effects. Common side effects reported following neffy include headache, nasal discomfort, throat irritation and feeling jittery.
ENDS
MEDIA CONTACT
|
Palin Communications |
CSL Seqirus 0422 424 338 |
| PBS Information: neffy is not listed on the Pharmaceutical Benefits Scheme |
Consumer Medical Information available at cslseqirus.com.au/products
About Anaphylaxis
Anaphylaxis is the most severe form of an allergic reaction and involves more than one body system, such as the skin, respiratory, gastrointestinal and cardiovascular systems.3
Symptoms include difficult or noisy breathing, swelling of the tongue, swelling or tightness in throat, wheeze or persistent cough, difficulty talking or hoarse voice, persistent dizziness or collapse. In young children it can also result in paleness and floppiness.3
About Allergy and Anaphylaxis Australia
Allergy & Anaphylaxis Australia is a registered charity and Australia’s only national patient support organisation, dedicated to helping individuals and carers alike in managing allergic disease. They work to raise awareness of allergic conditions in the community and provide credible, evidence-based information, resources and services to support Australians with allergic disease and those who care for them.
About Allergy250K
Allergy 250K provides age-appropriate information and resources to assist young people who are living with severe allergies, and to help them to feel more connected with other teens and young adults going through similar experiences in a fun but informative way.
About CSL Seqirus
CSL Seqirus is part of CSL Limited (ASX: CSL). As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.
In Australia, CSL Seqirus operates the only local manufacturing facility for seasonal and pandemic influenza vaccine, and produces a range of unique medicines in the national interest, including antivenoms and the world’s only human vaccine for Q fever. Our commitment to Australia’s health also extends to providing access to paediatric and adult vaccines, and innovative pharmaceuticals for patients living with allergies, cardiovascular disease, severe pain, dry eye disease, iron deficiency, kidney and rare diseases.
Intended Audience
This press release is issued from CSL Seqirus is intended to provide information to about our business to media. Please be aware that information relating to the approval status and labels of approved CSL Seqirus products may vary from country to country. Please consult your local regulatory authority on the approval status of CSL Seqirus products.
Additional information
In relation to this CSL Seqirus media announcement, no honorarium was provided to Professor Connie Katelaris AM or Maria Said AM. Both have been briefed by CSL Seqirus on the TGA-approved use of this product.
For information on CSL products or to report an adverse event involving a CSL product, please contact CSL Seqirus on 1800 642 865.
neffy is distributed by Seqirus Pty Ltd ABN 26 160 735 035 655 Elizabeth Street Melbourne, Vic, 3000 Australia Telephone: 1800 642 865 www.cslseqirus.com.au
neffy is a registered trademark of ARS Pharmaceuticals Operations, Inc.
REFERENCES
- neffy approved Consumer Medicine Information: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2025-CMI-02437-1&d=20251218172310101
- ARTG. 2025. Available at: https://www.tga.gov.au/resources/artg/42978. Accessed October 2025.
- ASCIA. Analphylaxis Fast Facts. Available at: https://www.allergy.org.au/patients/fast-facts/anaphylaxis. Accessed February 2026.
- Parliament of the Commonwealth of Australia. 2020. Available at: https://parlinfo.aph.gov.au/parlInfo/download/committees/reportrep/024422/toc_pdf/Walkingtheallergytightrope.pdf;fileType=application%2Fpdf. Accessed October 2025.
- Mullins RJ, et al. Clin Exp Allergy. 2016;46;1099–1110.
- Australian Commission on Safety and Quality in Health Care. 2021. Available at: https://www.safetyandquality.gov.au/standards/clinical-care-standards/acute-anaphylaxis-clinical-care-standard. Accessed October 2025.
- ASCIA. 2023. Available at: https://www.allergy.org.au/hp/papers/acute-management-of-anaphylaxis-guidelines. Accessed October 2025.
Date approved: February 2026
AU-NEF-25-0050
CSL Seqirus is a CSL Limited company, ASX:CSL ABN: 26 260 735 035
